|
|
Masterclasses:
Pre-conference
2th June 8am - 6pm
Influenza Vaccines Summit
Post-conference
5th June 8am - 6pm
A: Designing, commissioning & validation of cGMP facility & utility systems for the vaccine facility
B: Practical application of risk management in vaccine compliance & quality assurance
Conference:
Day 1
3th June 8am - 6pm
Special feature: Country Rooms
Day 2
4th June 8am - 6pm
Breakout A: Next generation vaccines, novel adjuvants & delivery systems
Breakout B: Vaccine production & supply
|
|
|
|
Meet our speakers
Dato' Dr Nor Shahidah Khairullah, Member of National Technical Committee on Vaccine Policies and Practices & Chairman of Subcommittee on New Vaccines,
Ministry of Health
|
|
Director of Disease Control Department,
Ministry of Health
|
|
|
Daniel Adams became CEO of Protein Sciences in 1995. He has previously founded and managed biopharmaceutical companies that have a combined market value of over $10 billion. He co-founded Biogen (OTC-BGEN) and served as its first President and CEO, founded and was CEO of Advanced Genetic Sciences Inc. ("AGS"), and co-founded Plant Genetic Systems in 1982. Dan holds a BA degree in Chemistry from Cornell University and a JD magna cum laude from New York University School of Law.
|
|
Executive Director,
Shantha Biotechnics Pvt. Ltd
Mr. Khalil Ahmed is the Executive Director (C.O.O.) since year 2000. Today, Shantha Biotech is the first name that comes to mind when people talk about the biotech industry in India.
Shantha has a joint venture established in U.S.A. The US venture is a research project in the area of cancer therapeutics.
|
|
Executive Vice President and Chief Scientific Officer,
Cytos Biotechnology
Martin F. Bachmann obtained his Masters degree in cell biology from the ETH Zürich, Switzerland and received his Ph.D. in Immunology in 1995 from the Institute for Experimental Immunology, Zurich, Switzerland, in the laboratories of Prof. Rolf Zinkernagel and Hans Hengartner. As the CSO of Cytos Biotechnology AG since October 1999, he applied his extensive immunological experience to generate novel types of vaccines, tackling chronic disease such as hypertension, drug addiction or Alzheimer`s disease. His main current research interest is in understanding the rules that govern the induction of protective immune responses and how these insights translate into the development of optimized vaccine strategies. He received the Pfiizer Prize for Immunology (Switzerland), two silver medals of the Swiss federal Insitute of Technology and the Swiss technology award. He has more than 170 publications in peer reviewed journals.
|
|
Vice President Business Development,
Vaxinnate
Dr. Becker joined VaxInnate in December 2005 with 15 years of vaccine development and industry experience at Sanofi Pasteur, leaving as a Vice President of Corporate Development. With eight years of business development experience, he has expertise in identifying, assessing, negotiating and managing collaborative product development relationships with large pharmaceuticals, biotechnology companies, academic institutions and government agencies, having secured over 30 technologies and products. Prior to his business responsibilities, Dr. Becker headed the immunology section and a vaccine development project at Sanofi Pasteur. His academic experience included junior facility positions at Loyola University Chicago and University of Illinois Chicago in the field of Immunology. Dr. Becker received his Ph.D. in Microbiology and Immunology from the University of Kansas and his MBA from Columbia University.
|
|
Director, Quality Management and Commercial Affairs,
Malaria Vaccine Initiative
Carla Botting directs the Quality Management and Commercial Affairs unit, which comprises four sets of activities: monitoring and evaluation and quality assurance (excluding clinical quality assurance), including manufacturing quality assurance; regulatory affairs; manufacturing; and business development.
Carla has more than ten years of industry experience in business development and in the development and approval of biologics. Prior to joining MVI, Carla was the Director of Government Business Development at Cangene Corporation, where she oversaw program management, business development, and government relations in the United States and other industrialized countries.
|
|
Dr Eduardo Bruno Martins, Vice President, Clinical Development,
Dynavax
Dr. Martins joined Dynavax in March 2006 as Vice President, Clinical Development. Eduardo came to us from InterMune, where he was Vice President, Medical Affairs. From 1999 to 2005, Dr. Martins was Vice President, Medical Affairs and Medical Director at SciClone Pharmaceuticals, where he also served as Medical Consultant from 1997 to 1999. He received a Ph.D. in Medicine - Immunology of Liver Diseases from the University of Oxford in 1995 and an M.D. from the Federal University of Rio de Janeiro in 1986.
|
|
Executive Vice President, Head of R&D,
Green Cross
Chong-Hwan Jonathan Chang, Ph.D currently serves as Executive Vice President and Head of R&D at Green Cross, focusing on the development of various biopharmaceutical products including vaccines. Prior to joining the company, he has held different corporate positions in pharmaceutical companies in the US for the past 14 years. He has extensive knowledge and experience in protein crystallography and drug discovery at DuPont and BMS.
|
|
Director, Vaccine R&D Center ,
National Health Research Institutes
Dr. Chong had spent 15 years at Aventis Pasteur in human vaccine research and development. During his tenure there, Dr. Chong had developed two human vaccines, ProHibit against H. influenzae type b and the component pertussis vaccine, and also took a synthetic peptide-based HIV vaccine to phase I clinical trials in 1994. In 2003, Dr. Chong joined National Health Research Institutes (NHRI) to set up a newly created Vaccine Center for Research and Development. His current research and product development are avian flu inactivated vaccine, enterovirus 71 inactivated vaccines, meningococcal group B subunit vaccine, dengue subunit vaccine and CTL epitopes based HPV vaccines. Dr. Chong’s laboratory is also currently developing (1) Asian specific reagents for monitoring human cellular immune responses to vaccines, (2) universal carrier proteins for glycoconjugations, and (3) viral vectors for mucosal vaccine delivery. Dr. Chong has authored over 80 original research articles and over 40 patents grants.
|
|
Dr Tawee Chotitayasunondh, Bird Flu Expert, Chief of Clinical Management Team, Pandemic Influenza,
Ministry of Public Health, Medical Services
Dr.Tawee Chotpitayasunondh is the Associate Professor, Senior Consultant Level 11, of Pediatric Infectious Diseases Specialist at the Queen Sirikit National Institute of Child Health. Having been a pediatric infectious diseases specialist for 30 years eg. TB, HIV/AIDS, Antibiotic, Vaccine, SARS, Avian flu, he had won professional awards - Charles C Shephard Science Award 2000 from US-CDC and Best Research Award 2000 from MOPH,Thailand. He has written 40 scientific publication in many Thai and English Journals and 20 chapters of Pediatric ID in many textbooks.
|
|
Senior Medical Advisor, DDC,
Ministry of Public Health, Thailand
Dr Supamit supervises the national immunization program (EPI) and heads Poliomyelitis Eradication Coordination office under DDC, MOPH. Trained in medicine, field epidemiology and public health; since 1985 Dr Supamit has served in the technical aspects and coordination of several disease control programs including hepatitis B, dengue, diarrheal diseases, emerging infectious diseases, and EPI. Over twelves years in EPI, he was involved in introductions several new vaccines including hepatitis B, Japanese encephalitis and measles-mumps-rubella vaccines. Now he is also a secretary of the newly established National Vaccine Committee. Since 2003 he has served as a key technical staff for MOPH in the development and coordination of policy and strategies for preparedness and response to emerging infectious diseases including SARS, avian influenza and the threats of pandemic influenza.
|
|
Vaccines Research Site Head, Ottawa Laboratories,
Coley Pharmaceutical Group
Dr. Davis joined Pfizer’s Vaccine Research Division following the acquisition of Coley Pharmaceutical Group by Pfizer in January 2008. Dr. Davis was a scientific co-founder of Coley (1996), and served as Managing Director of Canadian operations and Senior Vice President, Pharmacology R&D. Dr. Davis previously held academic positions at University of Ottawa (Professor) and McGill University, Montreal and carried out pioneer work with DNA vaccines and CpG adjuvants. Dr. Davis holds a PhD in Anatomy from the University of Western Ontario.
|
|
Chief Executive Officer and Chairman,
Emergent BioSolutions Inc.
Mr. Fuad El-Hibri is currently the Chairman and Chief Executive Officer of Emergent BioSolutions Inc., a biopharmaceutical company focused on developing vaccines and therapeutics to prevent and treat life-threatening diseases. Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. in the United Kingdom. He led the reorganization of Porton into Speywood Holdings, Ltd., where he served on the Board of Directors, and helped orchestrate its subsequent sale.
|
|
Director, Division of Vaccine Preventable Disease Control & National Immunisation Programme,
Korea Center For Disease Control & Prevention
Professional Experience includes Research Scientist, Division of Epidemic Intelligence Service, Korea National Institute of Health (hereinafter, KNIH), Vice-Director, Division of HIV and TB Control, Korea Center for Disease Control & Prevention (hereinafter, KCDC) and Director, Division of VPD Control & NIP, KCDC (2005 - current ). Research interests includes - HIV Control, Vaccine Preventable Disease Control (TB, Influenza, Measles, Hepatitis B) and Communicable Disease Epidemiology.
|
|
|
Dr. Goldwaser's career in the bio-pharmaceutical industry began over a decade ago, spanning executive and R&D management roles in the biotechnology, chemical and biological drug development markets. Dr. Goldwaser served as CEO of NasVax from its foundation until March 2007. Dr. Goldwaser joined NasVax from Sol-Gel Technologies, where he served as
CTO and Chief Biologist and R&D Project Manager overseeing the Company's experiments, worldwide collaborations, IP management, R&D and drug-candidate evaluation. Prior to that, Dr. Goldwaser worked as Lapid Pharmaceuticals' R&D Manager and Supervisor from 1999 through 2002.
|
|
Chief Scientific Officer,
Crucell
As per March 2002 Jaap Goudsmit is affiliated with Crucell, a leading biotechnology company in Leiden. He started as Senior Vice President Vaccine Research. In July 2002 he accepted the position of Chief Medical Officer and became a member of the Executive Committee as Executive Vice President Vaccine Research and Development. Since September 2002 he holds the position of Chief Scientific Officer and Head Research and Development. In January 2004 he became a member of Crucell's Management Board.
In August 2003 Jaap Goudsmit accepted his appointment as chairman of the board of the AIDS Foundation East-West, an NGO focused on AIDS prevention in the countries of the former Soviet Union.
In December 2003 Jaap Goudsmit has been elected as member of the HIV Vaccine Enterprise Product Development Working Group of the Gates Foundation.
Since March 2006 Jaap Goudsmit is affiliated with Pevion as member of the Supervisory Board. In the same month he entered the Board of Vaxin Inc. Also in 2006 Jaap Goudsmit accepted his appointment as member of the Scientific Advisory Board of the Eurovacc Foundation.
|
|
Head Vaccine Initiative Asia,
GE Healthcare Life Sciences
Sophie Guo joined the company in 1997, worked in China for 4 years as Marketing leader, focused on downstream processes and process scaling up. Worked in the same company in Sweden for 6 years, has been product manager for Bioprocess media, recent years working mostly with the focus on Asia. Lately her primary role is to head the vaccine initiatives in Asia.
|
|
Director-General,
National Institute of Hygiene & Epidemiology
He is currently the Director for Center for HIV/AIDS Research and Training, Hanoi Medical University and Director of National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. He is also the Vice-Chairman, National Committee of Prevention and Control of Human Avian Influenza and Pandemic.
|
|
President,
National Institute of Vaccines and Biological Substances (IVAC)
Dr Le Van Hiep, Professor, PhD of Medical Microbiology currently serves as Director of Institute of Vaccines and Medical Biologicals (IVAC, Vietnam). He spent 32 years at Vaccine Technology at NIHE (National Institute of Hygiene and Epidemiology) and IVAC. IVAC is the biggest and first quality manufacturer of vaccine and biologicals in Vietnam and accepted by UNICEF in 2007.
|
|
Director General, Communicable Disease Control and Environtmental Health,
Ministry of Health, Indonesia
|
|
Vice President, Global Marketing,
Baxter Vaccines
Peter H. Khoury, Ph.D., MBA is the Global Vice President for Baxter Vaccines. He obtained his docterate in Microbiology from Syracuse University in 1991, studying the effects of heat shock proteins on the resistance of bacterial spores. Dr. Khoury also holds a MBA from Cornell University's Johnson Graduate School of Management in marketing and general management.
Dr. Khoury’s current responsibilities in his position as Vice President, Global Marketing for Baxter International (BioScience Division) includes both vaccines sales and marketing for Latin America, North America, Asia, and the Pacific Region, government contracting, and business development.
|
|
Senior Technical Officer,
PATH
Over the last 18 years, Ms. Kristensen has led projects at PATH that focus on the advancement of novel technologies to improve immunization in resource-poor settings. She currently leads a research project to explore the technical and commercial feasibility of technologies to improve the thermostability of vaccines. In addition, Ms. Kristensen is working on the new World Health Organization/PATH partnership (entitled “Optimize: Immunization Systems and Technologies for Tomorrow”) that will endeavor to create a shared vision among stakeholders about the future supply and delivery systems for vaccines and other health products. Ms. Kristensen is experienced in product development; clinical, field, and laboratory evaluations; private/public partnerships; technology transfer; business development; global policy; and product introduction.
|
|
Deputy Director, PDVI,
International Vaccine Institute
Joel Kuritsky, M.D. is the Deputy Director of the Pediatric Dengue Vaccine Initiative effective September 18, 2006. He has twenty-five years of public health experience. He retired from the United States Public Health Service at the Centers for Disease Control in July of 2005, after 23 years of service. In his career at CDC, Dr. Kuritsky served as an EIS Officer in Atlanta and the state of Minnesota, was the Deputy and then Director of the Immunization Services Division in the National Immunization Program. From 2001 to 2002 he served as a principle advisor to the Director of the National Immunization Program for Smallpox preparedness. From 2002 to 2005, he was the branch chief and advisor to the director of the Treatment and Care Branch in the Global AIDS Program.
|
|
Vice President, Corporate Development,
sanofi pasteur
Bertrand Lépine, VP Corporate Development for Sanofi Pasteur, has more than 22-year of experience in the vaccine industry, focusing his career mainly in the field of Marketing, Commercial as well as Business Development, in setting up various partnerships with local producers worldwide, particularly in Asia: After his graduation as Medical Doctor in Lyon, France, he started his career as a marketing consultant for the pharmaceutical industry and joined in 1986 Sanofi Pasteur (at that time Institut Mérieux) as medico-marketing support in France. Later, as International Group Product Director, he was in charge of the marketing of a full line of vaccines. In 1992, he had direct operational responsibilities in Asia, as Area Director, with the opportunity to negotiate new partnerships which are still active today. Since 1999, B. Lépine has been leading the International Business Development activities, such as worldwide distribution agreement, acquisition, JV and technical cooperation.
|
|
Director, Department of Manufacturing Coordinate,
China National Biotec Group (CNBG)
Liu Baokui, M.D., the Director of the Department of Manufacturing Coordinate, is in charge of vaccine production and quality management in China National Biotec Group, and the member of Pharmacopoeia Commission of the Peoples’s Republic of Chian. In 1978 - 1988, worked in the Department of Epidemiology in the National Vaccine & Serum Institute (NVSI) as the Assistant Researcher for the clinical trial of bacteria vaccine. In 1989 - 1991, engaged in bacterial conjugate vaccine development as a Visiting Scientist in the National Institutes of Health in U.S.A. In 1993 - 1998, was the Director of the Department of Bacterial Vaccine at NVSI for the management of bacterial vaccine production. In 1999 -2006, was the vice manager of the Department of Quality Control and Quality Assurance, and the Vice Chief Engineer at Beijing Tiantan Biological Products corporation Ltd.
|
|
Dr Patricia London-Arcila, Senior Director of Immunology,
Acambis Inc
Patricia is Senior Director of Immunology at Acambis, as well as Project Leader of the Influenza Vaccine program. In the latter capacity, Patricia heads a multidisciplinary team responsible for driving the development of our Universal Influenza vaccine candidate, ACAM-FLU-A™.
As Director of the Immunology Department, which Patricia set up, she is responsible for various immunological aspects of our vaccine development process. This encompasses testing immunogenicity and efficacy in animal models, characterising immune responses during clinical testing and developing analytical methods needed for process development and formulation. Their attention presently focuses on subunit vaccines for Influenza and C. difficile, as well as live attenuated vaccines against Genital herpes and West-Nile infection, among others.
|
|
Professor Barry Marshall, Director, Chief Executive & Chief Scientist,
Ondek
Professor Barry J. Marshall is the co-discoverer of the H. pylori organism, a world authority on H.pylori and co-recipient of the Nobel Prize for Physiology or Medicine 2005. The hypothesis that H.pylori is a causative factor of stomach cancer was accepted in 1994 by the World Health Organisation. This work has now been acknowledged as the most significant discovery in the history of gastroenterology and is compared to the development of the polio vaccine and the eradication of smallpox. Professor Marshall is the Chief Scientific Officer and Chief Executive Officer of Ondek. He is also a clinical professor at the University of Western Australia and a practising specialist gastroenterologist.
|
|
Mr Jacques-Francois Martin, President,
Parteurop
Jacques-François Martin has spent the essence of his career in the pharmaceutical, biological and life sciences industries. In 1991, Martin set up Parteurop S.A, a biotech consulting company based in Lyon, France. At Parteurop, Martin as Chairman and CEO, helps establish start-up companies by leveraging innovation from French and foreign institutions.
From November 1997 to June 2003 he was a member of the Board of the International AIDS Vaccine Initiative (IAVI).
From 2000 to January 2005, Martin held the position of President of The Vaccine Fund. He lead the Fund’s efforts to provide lifesaving vaccines and other immunization program support to low-income countries. In this capacity, he was also a member of the Board of GAVI (Global Alliance for Vaccines and Immunization).
|
|
Senior Technical Advisor,
USAID
|
|
VP Quality & Regulatory Compliance,
Intercell
|
|
Director, Infectious Disease Surveillance Center,
National Institute of Infectious Disease
|
|
Managing Director,
Green Cross Vaccines
I am working at GCC for 29years. My major is virology. I am interested in the development of virus vaccine field, especially for Influenza, Varicella- zoster and Hepatitis A virus. I am also a charge of production of these vaccines in GCC.
|
|
Professor Nikolai Petrovsky, Chairman,
Vaxine Australia
|
|
Senior Director ,
Serum Institute of India
|
|
Marketing Manager,
Pall Life Sciences
Bruce Rawlings is a Marketing Manager in the BioPharmaceutical division of Pall Life Sciences. During his 14 years at Pall he has worked in Quality Assurance and in Pall’s Scientific and Laboratory Services (SLS) providing technical support & training for Pall’s Biopharmaceutical customers. More recently, Bruce has supported the Pall tangential flow filtration (TFF) products as a Technical Specialist, Applications Engineer and Product Manager.
Bruce is currently a Marketing Manager for Single Use Systems, supporting the general product portfolio of Pall Allegro™ Single Use Technologies with a focus on tangential flow filtration technologies and applications and new technology development programmes.
|
|
Chief General Manager,
Indian Immunologicals
Dr.G.S.Reddy is the Chief General Manager of Indian Immunologicals Limited, a major veterinary and human vaccines manufacturer in India. He obtained basic degree in Veterinary medicine in 1981 from Andhra Pradesh Agricultural University, Hyderabad.
He has 25 years of experience in industry, developing veterinary and human biologicals. Experience encompasses Quality, Research and Development, Manufacturing and Regulatory affairs. He is heading the team which is involved in manufacturing of various veterinary biologicals and human vaccines such as recombinant hepatitis B, Measles, DPT, TT, DT and DPTH vaccines. He worked on collaborative vaccine development projects with Georg August University, Gottingen, Germany and Centers for Disease Control and Prevention(CDC), Atlanta, USA. He is co-author of patent on DNA Rabies vaccine. He has published 40 scientific papers in various journals.
|
|
Director and Founder,
Infectious Disease Research Institute
Steven G. Reed, Ph.D. is the founder and scientific director of the Infectious Disease Research Institute (IDRI). Dr. Reed was co-founder and Chief Scientific Officer of Corixa Corporation, which was founded in 1994 and sold to GlaxoSmithKline in 2005. In 2005 he founded Dharma Therapeutics, a Seattle biotech developing transdermal delivery systems. He also serves as Director and CSO of Transcu, Ltd., the parent company of Dharma. Transcu Ltd. is based in Singapore. His academic appointments include Professor of Global Health at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Study Section of the National Institutes of Health and the Vaccine Development Steering Committee of the World Health Organization, and is currently a member of the Diagnostics Steering Committee of WHO.
|
|
|
Joe Santangelo is the CEO and a founder of SingVax Pte. Ltd (incorporated in 2004), which is a privately held Singapore biotech company focusing on vaccines for human health. Prior to this he was one of the founding scientists of Microscience Ltd., where he served in R&D roles from its inception as a spin out from Imperial College of Science Technology and Medicine (UK) in 1997. His overall career in microbiology, infectious diseases and fermentation spans more than 25 years. Joe was born, educated and worked in the United States, before moving to South Africa, Germany, the United Kingdom and Singapore. He has worked in both academia and industry, and moved to the biotech sector 10 years ago.
|
|
Head, Division of Bioregulation Research,
St. Marianna University School of Medicine
Ken-ichiro Seino, M.D., Ph.D. was gradated from School of Medicine, University of Tsukuba, Japan, in 1991. After finishing a residency course in Surgery, he entered a Ph.D. course of University of Tsukuba. He studied transplantation and tumor immunology there, and obtained his Ph.D. in 1997. He was a research fellow of the Japan Society for the Promotion of Science from 1996 to 1999, and a young researcher of Japan Science and Technology Agency from 2000 to 2003. He served as an assistant professor of Department of Surgery, University of Tsukuba since 1999 to 2002. He became a senior scientist at Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology since 2002 to 2006. He has been a Director of Division of Bioregulation Research, Institute of Medical Science, St. Marianna University School of Medicine since 2006.
|
|
Chief Executive Officer,
Medicago
Mr. Sheldon has been President and Chief Executive Officer of Medicago since August 2003. He has over twenty years of experience in the pharmaceutical industry. Before joining the company, Mr. Sheldon was Vice-President, Sales and Marketing, of Shire Biologics. He was responsible for international expansion with European, American and Asian private partnership agreements. He was also responsible for distribution, customer, and maintenance and engineering at the Shire facility. He successfully negotiated the annual and pandemic contract with the federal and provincial governments. From 1998 to 2000, he was Senior Manager of Commercial Operations where successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA.
|
|
Director, Vaccines Research,
Novartis Vaccines and Diagnostics
|
|
Senior Programme Officer, Policy & Finance,
Bill & Melinda Gates Foundation
Kanwarjit Singh was educated in Economics and Business at Oxford University ( MPhil Economics) and MIT ( MBA) and in Medicine at Columbia University (MD). He subsequently practiced medicine before transitioning to the biotech and pharma sectors where he worked as a consultant at McKinsey and Company and in roles of increasing responsibility in product development and commercialization and strategic planning and business development at Glaxo, Amgen and Bayer. He is now with the Bill and Melinda Gates Foundation where he is with the Business Planning Group working on the Foundation's portfolio of vaccine initiatives. He is a frequent participant in industry symposia and events as a speaker.
|
|
Senior Director, Vaccine Assessment,
Aeras TB Foundation
Dr. Donata Sizemore joined the Aeras Global TB Vaccine Foundation in 2007 as Senior Director of Vaccine Assessment. She has over 16 years of experience in infectious disease antigen discovery and vaccine development, with 10 years in the biotechnology industry. Prior to joining Aeras, Dr. Sizemore was the Project Manager for Battelle in Columbus, Ohio at the Biomedical Research Center. Among her many responsibilities, she was the Project Manager for a multi-million dollar, multi-task ID/IQ Umbrella Contract for the DMID/NIAID/NIH. Dr. Sizemore is best known for her work in construction and evaluation of bacterial delivery of recombinant proteins and plasmid DNA.
|
|
Regional Process & Product Development Manager,
World Courier Singapore Pte Ltd
Stanley has about 5 years of working experience in the aviation and courier industries. He has been with World Courier for 3 years. He started out as a National Operations Manager for Singapore before moving to the regional team as a Regional Process & Product Development Manager. In the current position, Stanley is involved in developing cold chain packaging solutions for customers. He is also a certified IATA DGR (Dangerous Goods Regulations) instructor as well as a Cold Chain Management Awareness Course Trainer
|
|
Co-founder & CEO,
Inviragen
Dr. Dan Stinchcomb is Chief Executive Officer, co-founder and President of Inviragen, a biotechnology company focused on developing life-saving vaccines for emerging infectious diseases worldwide. Since initiating operations for Inviragen in January, 2005, Dr. Stinchcomb successfully raised over $5.2 million in grant and seed investor funding, established Inviragen’s product and business strategies, opened its office and laboratory facilities in Fort Collins, established key collaborations with international vaccine manufacturers, non-profit vaccine initiatives, government research organizations and university researchers. Dr. Stinchcomb brings over twenty years of biotechnology management and scientific experience to Inviragen. Formerly, Dr. Stinchcomb was Executive Vice President of Research and Development at Heska Corporation and held scientific management positions at Ribozyme Pharmaceuticals (now Sirna, acquired by Merck) and Synergen (acquired by Amgen). Prior to joining Synergen, Dr. Stinchcomb was an Associate Professor in Cellular and Developmental Biology at Harvard University. Dr. Stinchcomb is an inventor on over 20 issued US patents and has authored more than 30 scientific articles. He received his PhD degree in Biochemistry from Stanford University and a BA degree from Harvard. Dr. Stinchcomb is also an Adjunct Professor of Molecular Biology and Biochemistry at Colorado State University.
|
|
Director, Influenza Vaccine Franchises,
Novartis Vaccines and Diagnostics
Klaus Stohr is currently the Director of Influenza Franchises at Novartis Vaccine and Diagnostics whose responsibilities is to coordinate the work of the Novartis Influenza Franchises (Core Project Teams) on seasonal and pandemic influenza. Prior to joining Novartis, Dr. Stohr is the Special Advisor on Influenza Pandemic Vaccine Development under the WHO Initiative for Vaccine Research and coordinator of the World Health Organization's (WHO) Global Influenza Programme in the Division for Communicable Disease Surveillance and Response (CSR), where he is charged with coordinating the WHO Global Influenza Programme, including the WHO Influenza Surveillance Network, and advising WHO and national health authorities on policies and strategies for the surveillance and prevention of seasonal influenza and pandemic preparedness.
|
|
Director,
Division of Clinical Research, NHRI,
Ih-Jen Su, MD.,PhD. is currently the Director and Distinguished Investigator of the Division of Clinical Research, National Health Research Institutes, Taiwan ( 2002- ), and the jointly appointed Professor of College of Medicine, National Cheng Kung University. His major research interests are in the pathogenesis and therapy of EBV-related lymphoma and HBV-related hepatoma. In the past 10 years, he devoted himself to the control of infections diseases such as influenza, enteroviruses, and tuberculosis in Taiwan. He is the world pioneer scientist in the study of the pathogenesis of virus-associated T cell lymphoma and hemophagocytic syndrome. In recent years, he identified the pre-S mutants as the viral oncoproteins in HBV-related hepatocarcinogenesis. Many of his basic researches now come to the stages of clinical application and targeted therapy such as the application of PPAR agonists and NFkB inhibitors in the therapy of virus-associated cancers. He served as the Board members in many foundations, the editorial board of Cancer Science, and received many prestigious awards in the past years.
|
|
Vice President, Goverment Project Management,
Medimmune, Inc
Alan Taggart joined MedImmune as vice president, government project management in September 2006. In this role, he is responsible for coordinating and managing MedImmune’s government projects, including the recently awarded $170 million Health and Human Services cell culture contract. He is also responsible for identifying and capitalizing on additional government contracting opportunities.
|
|
Associate Professor,
The Australian National University
Dr Naresh Verma completed his PhD at the Department of Microbiology, University of Sydney in 1988. He has since pursued his research interests in microbial pathogenesis and vaccine development in post-doctoral fellowship appointments at the Karolinska Institute in Sweden and Howard Hughes Medical Institute at Stanford University, U.S.A. He returned to Australia to take up a lectureship at the Australian National University in 1993. He is currently Associate Professor of Microbiology at the School of Biochemistry and Molecular Biology, College of Science, Australian National University. He was awarded the Fellowship of the Australian Society for Microbiology (FASM) in 2005. His main research interests are Bacterial and bacteriophage genetics, and vaccine development.
|
|
Consultant,
PharmEng International
|
|
President, Biopharmaceutical R&D,
Panacea Biotec
He took up the current assignment as President and Head of Biopharmaceutical (R&D) at Panacea Biotec Ltd. in 2003 and has been instrumental in setting up a new R&D center for Biopharmaceutical programs of Panacea Biotech in 2005. He has more than 30 years of experience in Research, teaching and scientific administration in relation to medical biotechnology discipline. During his tenure in DBT, New Delhi he was instrumental in designing and implementing medical biotechnology and human genome programs for the country. He has published more than 225 research papers in International and National Medical journal of reputes high impact factors and has got ten National Awards for his Bio medical research activities. These awards have been conferred by Indian Council of Medical Research, Medical Council of India, National Academy of Medical Sciences and other scientific specialty bodies.
|
|
|
Steve has over 35 years experience in the Biotechnology and the Pharmaceutical industry in Quality Assurance, Manufacturing and Consulting. He has conducted numerous FDA and TGA/PICs compliance audits and gap analysis for many international companies as well as developed multiple training courses for GMP, GLP, Validation, Risk management, HACCP and Medical Devices. He regularly present at conferences and industry seminars on a range of subjects relating to QA, Risk Management and GMP compliance. He also specialise in e-Learning compliance training solutions for intranet delivery within Pharmaceutical companies.
Steve has consulted in GMP, GLP and validation since 1989 and has prepared many companies for regulatory in-spections. Steve is a registered auditor for the Australian Pesticides and Veterinary Manufacturing Authority (APVMA) and, in this role, conducts GMP licensing audits on behalf of the Australian government.
|
|
Director,
Chinese Center for Disease Control and Prevention, National Immunisation Programme
Dr. Xiaofeng Liang, serviced the director of National Immunization Programme (NIP), Chinese Center for Disease Control and Prevention today, with the Master Degree in the field of Epidemic & Public Health got from Union Public Health School of Peking Medical University College, China, 1995, and the Post-Doctor experience from Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Miami, Florida, US, 1996.4-1998.4.
He is a senior director in the field of vaccine preventable disease prevention and control.
He is also a senior scientist in the disease prevention and control, with tens of papers published in the Chinese Journal of Vaccines and Immunization.
|
|
Vice President,
China National Biotec Group
Dr. Bing ZENG is Vice President of China National Biotec Group (CNBG) and responsible for international cooperation and business development of CNBG. Prior to joining CNBG in 2004, Dr. ZENG served in various multinational biotech and pharmaceutical companies including Boehringer Mannheim, Organon Teknika (a business unit of AKZO Nobel) and BIOMERIEUX for many years both in China and in Europe. Dr. Bing ZENG received his MBA degree from Nijenrode University (now named NIJENRODE BUSINESS UNIVERSITEIT), The Netherlands Business School in The Netherlands, and his Medical Degree from Beijing Medical University (now named The Medical School of Peking University) in Beijng, China. He practiced in China-Japan Friendship Hospital in Beijing as a Physician before he pursued his career in biotech Industry.
|
|
|
Gerd Zettlmeissl joined Intercell as Chief Operating Officer in 2001. After having been responsible for Business, R&D and Manufacturing Operations at Intercell for four years, Gerd Zettlmeissl was appointed Chief Executive Officer in the fall of 2005. Gerd Zettlmeissl’s scientific background is in Molecular Biology and Protein Biochemistry. After five years of academic research at the University of Regensburg and at the Institut Pasteur in Paris, he joined Behringwerke AG (Marburg, Germany) in 1985.
|
|
Medical Officer, Influenza Surveillance,
World Health Organisation
Dr Zhou is the Influenza Coordinator in the World Health Organization (WHO) Regional Office for the Western Pacific in Manila, Philippines with the responsibility of influenza surveillance and control. Before joining WHO, Dr Zhou was a Medical Epidemiologist at the Influenza Division of the US Centers for Disease Control and Prevention. He had more than twenty years of experiences in clinical medicine, biomedical research, and public health services. He was involved in the investigation and control of SARS outbreaks in 2003 and has been working on the surveillance and control of influenza including influenza A/H5N1 in the WHO Western Pacific Region since 2005.
|
|
|
|
|
|
|
WVC Asia 2008 speakers include
Adel Mahmoud
Former President, Merck Vaccines, USA
Klaus Stohr
Director, Influenza Vaccine Franchises, Novartis Vaccines & Diagnostics, USA
Debra Kristensen
Senior Technical Officer,
PATH, USA
Xiaofeng Liang
Director, Chinese CDC & Prevention, National Immunisation Programme, China
Chong-Hwan Chang
Vice President,
Head of R&D,
Green Cross, Korea
|
|
As a speaker, you are able to:
- Enhance your personal and public standing as a recognised leader in the industry
- Lead and shape your market
- Capitalise on meeting all the best people
- Discover prime research partnership opportunities all under one roof
- Obtain excellent returns saving your time and energy travelling around the region
|
|
|
|
|
